Evaluation of in vitro and in vivo release of recombinant human nerve growth factor from bioengineered human stromal lenticule
Bioengineered lenticules exhibit sustained rhNGF release for at least 7 days <i>in vitro</i> and up to 1 month <i>in vivo</i>. These results, together with absence of adverse effects, and significant increase in CNFD at 4 weeks after lenticule implantation suggest its promising potential for clinical use.
Authors
- Domitilla Mandatori (ORCID: https://orcid.org/0000-0001-9815-5200)
- Harminder Singh Dua (ORCID: https://orcid.org/0000-0002-4683-6917)
- Mario Nubile
- Nicola Detta (ORCID: https://orcid.org/0009-0007-0877-9839)
- Isabelle Xin Yu Lee
- Franca Cattani (ORCID: https://orcid.org/0000-0002-3873-9295)
- Tiziana Romeo
- Jodhbir S. Mehta
- Assunta Pandolfi (ORCID: https://orcid.org/0000-0003-4135-7631)
- Marcello Allegretti (ORCID: https://orcid.org/0000-0002-0617-0233)
- Letizia Pelusi
- Yuchi Liu (ORCID: https://orcid.org/0000-0003-3533-1697)
- Leonardo Mastropasqua (ORCID: https://orcid.org/0000-0003-4890-3834)
- Jing Han
- Molly Tzu-Yu Lin
Institutions
- Singapore National Eye Center (SG)
- Nottingham City Hospital (GB)
- University of Chieti-Pescara (IT)
- Singapore Eye Research Institute (SG)
- Dompé (Italy) (IT)
- Farmaceutici Damor (Italy) (IT)
Publication Details
- Journal
- Frontiers in Bioengineering and Biotechnology
- Published
- 2025-09-19
- DOI
- https://doi.org/10.3389/fbioe.2025.1588629
- Primary Topic
- Corneal Surgery and Treatments
- Type
- article
- Field-Weighted Citation Impact
- 0.00